Introduction The aim of this study was to report 36-month longitudinal changes using the North Star Ambulatory Assessment (NSAA) in ambulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53. Materials and methods We included 101 patients, 34 had deletions amenable to skip exon 44, 25 exon 45, 19 exon 51, and 28 exon 53, not recruited in any ongoing clinical trials. Five patients were counted to skip exon 51 and 53 since they had a single deletion of exon 52. Results The difference between subgroups (skip 44, 45, 51 and 53) was significant at 12 (p = 0.043), 24 (p = 0.005) and 36 months (p≤0.001). Discussion Mutations amenable to skip exons 53 and 51 had lower baseline values and more negative changes ...
The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of l...
peer reviewedThe aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and ...
Duchenne muscular dystrophy is a rare genetic disorder with life-limiting pathology. Drisapersen ind...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
peer reviewedINTRODUCTION: The aim of this study was to report 36-month longitudinal changes using t...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Introduction: The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne M...
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystroph...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of l...
peer reviewedThe aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and ...
Duchenne muscular dystrophy is a rare genetic disorder with life-limiting pathology. Drisapersen ind...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
peer reviewedINTRODUCTION: The aim of this study was to report 36-month longitudinal changes using t...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Introduction: The Performance of Upper Limb version 2.0 (PUL 2.0) is increasingly used in Duchenne M...
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystroph...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of l...
peer reviewedThe aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and ...
Duchenne muscular dystrophy is a rare genetic disorder with life-limiting pathology. Drisapersen ind...